Concepedia

Publication | Open Access

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

DOIFull Paper Access

208

Citations

17

References

2018

Year

Amit Bar‐Or, Richard Grove, Daren Austin, Jerry M. Tolson, Susan VanMeter, Eric Lewis, Frederick J. Derosier, Monica C. Lopez, Sarah Kavanagh, Aaron Miller,
Neurology

Abstract

This study provides Class I evidence that for patients with RMS, ofatumumab decreases the number of new MRI gadolinium-enhancing lesions 12 weeks after treatment initiation.

References

YearCitations

Page 1